Gilead Sciences Executive and Leadership Team

Andrew Dickinson, the Chief Financial Officer at Gilead Sciences, directs all global financial operations and capital allocation strategies. Managing the fiscal health of the organization, the Chief Financial Officer oversees investment in research and development for HIV, viral hepatitis, and oncology portfolios. Dickinson architects long-term financial planning to support the commercialization of medicines across the United States, Europe, and international markets. By analyzing market trends and collaboration agreements with partners like Arcus Biosciences and Merck, the Chief Financial Officer ensures sustainable growth and operational efficiency. This leadership role involves rigorous oversight of the balance sheet to maintain the capacity for innovation in biopharmaceuticals. Through disciplined capital management, Andrew Dickinson secures the resources necessary for the company to address critical unmet medical needs while delivering consistent value to stakeholders and maintaining a robust pipeline of therapeutic solutions.

Deborah Son, the Chief Marketing Officer, Supply Chain at Gilead Sciences, manages the commercial distribution and supply chain logistics for the company's diverse therapeutic portfolio. Overseeing the delivery of products like Biktarvy and Veklury, the Chief Marketing Officer, Supply Chain ensures that life-saving medicines reach patients across global markets efficiently. Son coordinates with manufacturing teams to maintain inventory levels for oncology and viral disease treatments, mitigating risks within the complex pharmaceutical supply chain. By aligning marketing strategies with logistical capabilities, the Chief Marketing Officer, Supply Chain optimizes product availability in both domestic and international regions. Deborah Son drives initiatives to streamline distribution channels, ensuring that the company meets the high demand for critical therapies. This role requires constant collaboration with internal stakeholders to maintain the integrity of the supply chain while supporting the broader mission of providing accessible healthcare solutions to patients worldwide.

Sonja Tong, the Executive Director and Chief of Staff at Gilead Sciences, coordinates executive operations and facilitates strategic alignment across the leadership team. Managing high-priority projects, the Executive Director and Chief of Staff ensures that corporate objectives regarding biopharmaceutical development remain on schedule. Tong synthesizes information from various departments to support decision-making processes for the executive suite. By streamlining communication channels, the Executive Director and Chief of Staff enhances operational agility within the organization. Sonja Tong monitors the progress of research collaborations and commercialization efforts, ensuring that the company maintains its focus on unmet medical needs. This role involves managing the flow of critical business intelligence to the leadership team, enabling effective responses to market shifts in the oncology and viral disease sectors. Through meticulous project management, Tong supports the execution of the company's long-term vision and operational excellence across all global business units.

Naomi Bautista, the Gain Chief of Staff (Gilead Asian Interest Network) at Gilead Sciences, directs internal initiatives that foster professional development and cultural integration within the organization. Overseeing the strategic goals of the network, the Gain Chief of Staff (Gilead Asian Interest Network) aligns employee engagement efforts with the broader corporate mission of innovation and inclusivity. Bautista manages programs that support the diverse workforce contributing to the discovery and development of medicines for HIV and oncology. By facilitating collaboration between internal groups, the Gain Chief of Staff (Gilead Asian Interest Network) strengthens the organizational culture, which directly impacts the company's ability to attract and retain top talent in the biopharmaceutical industry. Naomi Bautista ensures that internal networks contribute to the overall success of the company by promoting a collaborative environment. This leadership role involves executing projects that enhance employee connectivity and support the company's commitment to global health equity.

Christopher Iwata, the Chief of Staff To the Executive Vice President of Human Resources at Gilead Sciences, manages the operational priorities and strategic initiatives for the human resources division. Overseeing the alignment of talent management with the company's biopharmaceutical goals, the Chief of Staff To the Executive Vice President of Human Resources ensures that the workforce remains equipped to handle complex research and commercialization tasks. Iwata coordinates with leadership to implement organizational development programs that support the company's mission in oncology and viral disease treatment. By managing the flow of information and project timelines, the Chief of Staff To the Executive Vice President of Human Resources enables the HR leadership to focus on high-impact talent strategies. Christopher Iwata drives efficiency in HR operations, ensuring that the company maintains a competitive edge in the global pharmaceutical market. This role involves facilitating cross-functional collaboration to support the company's commitment to innovation and patient care.

Courtney Desmond, the Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer at Gilead Sciences, directs the operational activities of the ethics and compliance department. Overseeing the implementation of regulatory standards, the Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer ensures that all research and commercialization activities adhere to global legal requirements. Desmond manages the coordination of compliance programs that protect the integrity of the company's collaboration agreements with partners like Arcus Biosciences and Merck. By streamlining the communication of compliance policies, the Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer supports the company's commitment to ethical business practices in the United States and international markets. Courtney Desmond facilitates the execution of risk management strategies, ensuring that the organization maintains its reputation for excellence. This role involves managing critical projects that uphold the company's standards in the highly regulated biopharmaceutical industry.

Erik Schroeppel, the Chief Marketing Officer, Supply Chain & Manager at Gilead Sciences, manages the operational integration of marketing strategies with supply chain capabilities for specific therapeutic lines. Overseeing the regional distribution of oncology and viral hepatitis treatments, the Chief Marketing Officer, Supply Chain & Manager ensures that product supply meets the clinical needs of patients. Schroeppel coordinates with manufacturing and sales teams to optimize the availability of products like Epclusa and Harvoni. By managing the logistical aspects of product launches, the Chief Marketing Officer, Supply Chain & Manager supports the company's market expansion efforts. Erik Schroeppel drives efficiency in the supply chain, ensuring that the company maintains a reliable flow of medicines to healthcare providers. This role involves analyzing market demand and adjusting supply strategies to support the company's mission of addressing unmet medical needs. Through effective management, Schroeppel ensures that the company's commercial operations remain responsive to global health challenges.

Susanna Stinson, the Director, Research Chief of Staff and Strategic Projects at Gilead Sciences, directs the operational framework for the research and development division. Overseeing the execution of strategic projects, the Director, Research Chief of Staff and Strategic Projects ensures that the discovery of novel therapies for HIV, oncology, and viral hepatitis remains aligned with corporate goals. Stinson manages the coordination of research collaborations with partners like Merus N.V. and Assembly Biosciences, facilitating the development of trispecific antibodies and other innovative treatments. By streamlining research operations, the Director, Research Chief of Staff and Strategic Projects enables scientists to focus on high-impact drug discovery. Susanna Stinson drives the implementation of strategic initiatives that enhance the company's R&D pipeline. This role involves managing complex project portfolios and ensuring that research efforts contribute to the company's long-term success in the biopharmaceutical sector. Through meticulous oversight, Stinson supports the company's commitment to scientific innovation.